Deborah Watkins Bruner on Side Effects From Platinum-Based Drugs in Ovarian Cancer

June 17, 2015
Deborah Watkins Bruner, PhD, RN, FAAN

Sap Partners | Schools of Nursing | <b>Nell Hodgson Woodruff School of Nursing at Emory University</b>

Deborah Watkins Bruner, PhD, RN, FAAN, from the Nell Hodgson Woodruff School of Nursing at Emory University, discusses side effects associated with platinum-based drugs for the treatment of ovarian cancer.

Deborah Watkins Bruner, PhD, RN, FAAN, professor, Nell Hodgson Woodruff School of Nursing, Emory University, discusses side effects associated with platinum-based drugs for the treatment of ovarian cancer.

Related Content:

VideosGynecologic CancersAdverse Event Management
Maintenance PARP Inhibition Decisions in Ovarian Cancer
Factors Correspond With Higher Levels of Sleep Disturbance in Patients with GI Cancers
FDA Approves Dostarlimab for dMMR Advanced Endometrial Cancer